2024
Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study
Carmo H, Castillo A, Bonilha I, Gomes E, Barreto J, Moura F, Davanzo G, de Brito Monteiro L, Muraro S, de Souza G, Morari J, Galdino F, Brunetti N, Reis-de-Oliveira G, Carregari V, Nadruz W, Martins-de-Souza D, Farias A, Velloso L, Proenca-Modena J, Mori M, Loh W, Bhatt D, Yellon D, Davidson S, De Oliveira P, Moraes-Vieira P, Sposito A. Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study. Frontiers In Pharmacology 2024, 15: 1402032. PMID: 39434905, PMCID: PMC11491754, DOI: 10.3389/fphar.2024.1402032.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsHuman peripheral blood mononuclear cellsSARS-CoV-2 infectionSARS-CoV-2Viral replicationInflammatory responseInflammasome activationMarkers of inflammasome activationPlacebo-controlled studySuppress viral replicationBlood mononuclear cellsInfection in vitroPrimary metabolitesCOVID-19 patientsDouble-blindPrimary endpointHealthy volunteersSevere acute respiratory syndrome coronavirus 2Plasma markersAcute respiratory syndrome coronavirus 2Mononuclear cellsClinical trialsRespiratory syndrome coronavirus 2Day 2Syndrome coronavirus 2Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy
Moura F, Bellavia A, Berg D, Melloni G, Feinberg M, Leiter L, Bohula E, Morrow D, Scirica B, Wiviott S, Sabatine M. Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy. Diabetes Obesity And Metabolism 2024, 26: 4441-4449. PMID: 39056220, PMCID: PMC11410501, DOI: 10.1111/dom.15798.Peer-Reviewed Original ResearchNew-onset diabetesRisk of new-onset diabetesClinical risk modelWeight loss therapyRisk groupsWeight loss pharmacotherapyMultivariate Cox regressionStable cardiovascular patientsTherapeutic decision makingAbsolute risk reductionHigh-risk groupType 2 diabetesIndependent predictorsValidation cohortFollow-upPersonalized patient careCox regressionHazard ratioPrimary outcomeRisk modelHigh riskInterquartile rangePatientsDiabetesCardiovascular patients1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58
MI KANG Y, MELLONI G, CAHN A, RAZ I, MOURA F, BHATT D, INZUCCHI S, LEITER L, MCGUIRE D, WILDING J, GAUSE-NILSSON I, OSCARSSON J, MARSTON N, RUFF C, SABATINE M, WIVIOTT S. 1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58. Diabetes 2024, 73 DOI: 10.2337/db24-1896-lb.Peer-Reviewed Original ResearchDuke Clinical Research InstituteC-pepClinical Research InstituteDKA eventsC-peptideLower fasting C-peptideMedian follow-upRandomized to dapagliflozinFasting C-peptideDuration of T2DC-peptide testingRisk of DKACV outcome trialsAmerican College of CardiologyAbsolute risk differenceRate of DKAImpaired insulin secretionType 2 diabetesPlacebo armClinical featuresPopulation Health Research InstituteCSL BehringDiabetic ketoacidosisFerring PharmaceuticalsOutcome trials1895-LB: Fasting C-Peptide and Type 1 Diabetes Polygenic Score Predict Diabetic Ketoacidosis in People with Type 2 Diabetes in DECLARE-TIMI 58
MI KANG Y, MELLONI G, CAHN A, RAZ I, MOURA F, BHATT D, INZUCCHI S, LEITER L, MCGUIRE D, WILDING J, GAUSE-NILSSON I, OSCARSSON J, MARSTON N, RUFF C, SABATINE M, WIVIOTT S. 1895-LB: Fasting C-Peptide and Type 1 Diabetes Polygenic Score Predict Diabetic Ketoacidosis in People with Type 2 Diabetes in DECLARE-TIMI 58. Diabetes 2024, 73 DOI: 10.2337/db24-1895-lb.Peer-Reviewed Original ResearchRisk of DKADuke Clinical Research InstituteC-pepC-peptidePolygenic scoresClinical Research InstitutePopulation Health Research InstituteHigh-risk ptsFasting C-peptideHealth Research InstituteCV outcome trialsAmerican College of CardiologyHigher-risk groupsPredicting DKAType 2 diabetesCSL BehringDiabetic ketoacidosisFerring PharmaceuticalsBristol-Myers SquibbSt. Jude MedicalNon-HLAIncreased riskCleveland ClinicDapagliflozinAmerican CollegeOlezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Bergmark B, Marston N, Prohaska T, Alexander V, Zimerman A, Moura F, Murphy S, Goodrich E, Zhang S, Gaudet D, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano R, Sabatine M. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. New England Journal Of Medicine 2024, 390: 1770-1780. PMID: 38587249, DOI: 10.1056/nejmoa2402309.Peer-Reviewed Original ResearchConceptsNon-HDL cholesterolElevated cardiovascular riskLevels of triglyceridesTriglyceride levelsCardiovascular riskModerate hypertriglyceridemiaApolipoprotein BAdverse eventsNon-high-density lipoprotein (HDL) cholesterolLow-density lipoprotein (LDL) cholesterolBaseline to 6 monthsMedian triglyceride levelsRisk of adverse eventsLDL cholesterol levelsHigh cardiovascular riskTriglyceride-rich lipoproteinsApolipoprotein C-IIISevere hypertriglyceridemiaMedian ageTriglyceride loweringPlatelet abnormalitiesNo significant changesPlaceboPhase 2bPrimary outcomeDETECTION OF HYPERTROPHIC CARDIOMYOPATHY ON ELECTROCARDIOGRAM USING ARTIFICIAL INTELLIGENCE
Hillis J, Bizzo B, Mercaldo S, Ghatak A, Macdonald A, Halle M, Schultz A, L'Italien E, Tam V, Awad A, Bargiela D, Dagen S, Moura F, Toland D, Blood A, Gross D, Jering K, Lopes M, Marston N, Nauffal V, Dreyer K, Scirica B, Ho C. DETECTION OF HYPERTROPHIC CARDIOMYOPATHY ON ELECTROCARDIOGRAM USING ARTIFICIAL INTELLIGENCE. Journal Of The American College Of Cardiology 2024, 83: 2609. DOI: 10.1016/s0735-1097(24)04599-6.Peer-Reviewed Original ResearchAssessment of valve regurgitation severity via contrastive learning and multi-view video integration
Kim S, Ren H, Charton J, Hu J, Gonzalez C, Khambhati J, Cheng J, DeFrancesco J, Waheed A, Marciniak S, Moura F, Cardoso R, Lima B, McKinney S, Picard M, Li X, Li Q. Assessment of valve regurgitation severity via contrastive learning and multi-view video integration. Physics In Medicine And Biology 2024, 69: 045020. PMID: 38271727, DOI: 10.1088/1361-6560/ad22a4.Peer-Reviewed Original ResearchConceptsRepresentation learningContrastive learningMulti-view video processingState-of-the-art methodsContrastive learning frameworkState-of-the-artIn-house datasetVideo processingContrastive networkEmbedding spaceImage inputLearning frameworkVideo integrationIntricate taskLoss termMulti-modal clinical dataLearningRepresentationLabor-intensiveAccuracyEfficient methodVideo seriesEmbeddingDatasetNetwork
2023
Abstract 18949: Bariatric Surgery is Associated With Improved Coronary Microvascular Function and Cardiorespiratory Fitness in Patients With Ischemia and Non-Obstructive Coronary Arteries (INOCA)
de Souza A, Moura F, Divakaran S, Sirianni K, Sheu E, Di Carli M, Redline S, Tavakkoli A, Taqueti V. Abstract 18949: Bariatric Surgery is Associated With Improved Coronary Microvascular Function and Cardiorespiratory Fitness in Patients With Ischemia and Non-Obstructive Coronary Arteries (INOCA). Circulation 2023, 148: a18949-a18949. DOI: 10.1161/circ.148.suppl_1.18949.Peer-Reviewed Original ResearchCoronary flow reservePeripheral arterial tonometryCardiopulmonary exercise testingStress myocardial blood flowCoronary microvascular functionReactive hyperemia indexSevere obesityPeripheral endothelial functionPositron emission tomographyMyocardial blood flowBariatric surgeryEndothelial functionCardiorespiratory fitnessConsecutive patientsMedian ageIncidence of diabetic microvascular complicationsMicrovascular functionPost-surgeryNon-obstructive coronary arteriesImpaired coronary flow reserveMarkers of endothelial functionImpact of bariatric surgeryStress positron emission tomographyMethods Consecutive patientsResults Median ageComparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model
Nogueira A, Barreto J, Moura F, Luchiari B, Abuhab A, Bonilha I, Nadruz W, Gaziano J, Gaziano T, de Carvalho L, Sposito A. Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model. Health Economics Review 2023, 13: 50. PMID: 37878108, PMCID: PMC10599033, DOI: 10.1186/s13561-023-00466-3.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioGlucose-lowering therapyType 2 diabetesNetwork meta-analysisSecondary preventionPrevalence of type 2 diabetesBrazilian public health systemRisk of cardiovascular outcomesPublic health systemCost-effectiveReduced relative riskNon-fatal cardiovascular eventsContext of primary preventionConclusionsIn BrazilClasses of glucose-lowering therapiesHealth systemManagement of T2DMGLP-1aCost-effectiveness modelStandard carePrimary preventionCost-effectiveness ratioRelative riskEvidence-basedInternational dollarsMulti-task Learning for Hierarchically-Structured Images: Study on Echocardiogram View Classification
Charton J, Ren H, Kim S, Gonzalez C, Khambhati J, Cheng J, DeFrancesco J, Waheed A, Marciniak S, Moura F, Cardoso R, Lima B, Picard M, Li X, Li Q. Multi-task Learning for Hierarchically-Structured Images: Study on Echocardiogram View Classification. Lecture Notes In Computer Science 2023, 14337: 185-194. DOI: 10.1007/978-3-031-44521-7_18.Peer-Reviewed Original ResearchDeep learningMulti-task learning schemeVideo classification tasksMulti-task learningImage classification scenariosResidual neural networkData labelsClassification taskLearning schemeAblation studiesClassification scenariosNeural networkTree structureMedical imagesImage-processing techniquesSuperior performanceVideo viewingMonitoring cardiovascular diseasesTraining methodsHierarchically-structuredImage acquisitionLearningHierarchical structureTaskClassificationBody Composition, Coronary Microvascular Dysfunction, and Future Risk of Cardiovascular Events Including Heart Failure
Souza A, Rosenthal M, Moura F, Divakaran S, Osborne M, Hainer J, Dorbala S, Blankstein R, Di Carli M, Taqueti V. Body Composition, Coronary Microvascular Dysfunction, and Future Risk of Cardiovascular Events Including Heart Failure. JACC Cardiovascular Imaging 2023, 17: 179-191. PMID: 37768241, PMCID: PMC10922555, DOI: 10.1016/j.jcmg.2023.07.014.Peer-Reviewed Original ResearchConceptsCoronary microvascular dysfunctionVisceral adipose tissueAssociated with coronary microvascular dysfunctionCoronary flow reserveBody mass indexLow coronary flow reserveSubcutaneous adipose tissueCoronary artery diseaseAdverse eventsPositron emission tomographyObese patientsMicrovascular dysfunctionVisceral adipose tissue cross-sectional areaCardiovascular eventsHeart failurePreserved left ventricular ejection fractionAdverse outcomesSkeletal muscleArtery diseaseFlow-limiting coronary artery diseaseBody compositionAssociated with body compositionEvaluation of coronary artery diseaseStress positron emission tomographyEmission tomographyRisk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
Moura F, Berg D, Bellavia A, Dwyer J, Mosenzon O, Scirica B, Wiviott S, Bhatt D, Raz I, Feinberg M, Braunwald E, Morrow D, Sabatine M. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care 2023, 46: 1807-1815. PMID: 37556796, PMCID: PMC10516252, DOI: 10.2337/dc23-0492.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2Kidney disease progressionPredictors of kidney disease progressionAbsolute risk reductionDisease progressionValidation cohortType 2 diabetesSodium-glucose cotransporter 2 inhibitionUrine albumin-to-creatinine ratioAlbumin-to-creatinine ratioEfficacy of dapagliflozinMedian follow-upRisk categoriesMultivariate Cox regressionRelative risk reductionHigh-risk groupAtherosclerotic cardiovascular diseaseSystolic blood pressureRisk reductionMagnitude of benefitDapagliflozin EffectT2D durationCotransporter 2SGLT2 inhibitionStratify riskEfficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials
de Mesquita Y, Pera Calvi I, Reis Marques I, Almeida Cruz S, Padrao E, Carvalho P, da Silva C, Cardoso R, Moura F, Rafalskiy V. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. International Journal Of Obesity 2023, 47: 883-892. PMID: 37460681, DOI: 10.1038/s41366-023-01337-x.Peer-Reviewed Original ResearchConceptsMean differenceRandomized controlled trialsOdds ratioGlucagon-like peptide-1 receptor agonistsMeta-analysis of randomized controlled trialsPeptide-1 receptor agonistsControlled trialsMeta-analysisCo-primary endpointsMethodsWe searched PubMedType 2 diabetesAgonist tirzepatideRisk of biasReview Manager 5.4.1Receptor agonistsReduced BMITherapeutic optionsWaist circumferenceAdverse eventsTirzepatideGastrointestinal symptomsPooled analysisGLP-1PlaceboWeight management1704-P: Efficacy and Safety of Tirzepatide for Weight Loss—A Meta-analysis of Randomized Controlled Trials
MESQUITA Y, CALVI I, MARQUES I, CRUZ S, PADRAO E, CARDOSO R, MOURA F, RAFALSKIY V. 1704-P: Efficacy and Safety of Tirzepatide for Weight Loss—A Meta-analysis of Randomized Controlled Trials. Diabetes 2023, 72 DOI: 10.2337/db23-1704-p.Peer-Reviewed Original ResearchMean differenceDual glucose-dependent insulinotropic polypeptideOdds ratioGlucagon-like peptide-1 receptor agonistsMeta-analysis of randomized controlled trialsPeptide-1 receptor agonistsSafety of tirzepatideGlucose-dependent insulinotropic polypeptideCo-primary endpointsGastrointestinal side effectsWeight lossType 2 diabetesRandomized controlled trialsReceptor agonistsBody weight changesTherapeutic optionsAdverse eventsTirzepatidePooled analysisSide effectsPlaceboWeight managementControlled trialsMeta-analysisBody weightAssessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
Berg D, Moura F, Bellavia A, Scirica B, Wiviott S, Bhatt D, Raz I, Bohula E, Giugliano R, Park J, Feinberg M, Braunwald E, Morrow D, Sabatine M. Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. Journal Of The American College Of Cardiology 2023, 81: 2391-2402. PMID: 37344040, PMCID: PMC11466046, DOI: 10.1016/j.jacc.2023.04.031.Peer-Reviewed Original ResearchConceptsType 2 diabetes mellitusSecondary preventionIschemic strokePredictor of MIValidation cohortClinical decision-makingRates of MIMyocardial infarctionAtherothrombotic eventsRisk quintileRisk of atherothrombotic eventsRisk modelSelection of pharmacotherapyRisk scoreAssessed clinical variablesMultivariate Cox regressionClinical trial cohortPooled cohortCandidate variablesCox regressionIS ratesDECLARE-TIMIAbsolute reductionTrial cohortCohortRISK OF KIDNEY DISEASE PROGRESSION AND EFFICACY OF SGLT2 INHIBITION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Moura F, Berg D, Bellavia A, Mosenzon O, Dwyer J, Scirica B, Wiviott S, Bhatt D, Raz I, Feinberg M, Morrow D, Sabatine M. RISK OF KIDNEY DISEASE PROGRESSION AND EFFICACY OF SGLT2 INHIBITION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Journal Of The American College Of Cardiology 2023, 81: 1808. DOI: 10.1016/s0735-1097(23)02252-0.Peer-Reviewed Original ResearchASSOCIATION OF BASELINE MODEST ALCOHOL CONSUMPTION AND CORONARY MICROVASCULAR DYSFUNCTION IN THE CARDIOVASCULAR INFLAMMATION REDUCTION TRIAL (CIRT-CFR)
De Souza A, Moura F, Hainer J, Skali H, Blankstein R, Dorbala S, Hage F, Beanlands R, Ridker P, Di Carli M, Taqueti V. ASSOCIATION OF BASELINE MODEST ALCOHOL CONSUMPTION AND CORONARY MICROVASCULAR DYSFUNCTION IN THE CARDIOVASCULAR INFLAMMATION REDUCTION TRIAL (CIRT-CFR). Journal Of The American College Of Cardiology 2023, 81: 1499. DOI: 10.1016/s0735-1097(23)01943-5.Peer-Reviewed Original ResearchGENETIC PREDISPOSITION TO ADIPOSITY IS ASSOCIATED WITH GREATER RISK OF SUBSEQUENT HEART FAILURE EVENTS IN INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS
Moura F, Melloni G, Wilding J, Berg D, Bhatt D, Leiter L, Mosenzon O, Raz I, Scirica B, Wiviott S, Ellinor P, Florez J, Sabatine M, Ruff C, Marston N. GENETIC PREDISPOSITION TO ADIPOSITY IS ASSOCIATED WITH GREATER RISK OF SUBSEQUENT HEART FAILURE EVENTS IN INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS. Journal Of The American College Of Cardiology 2023, 81: 1638. DOI: 10.1016/s0735-1097(23)02082-x.Peer-Reviewed Original ResearchRELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58
Small A, Berg D, Raz I, Goodrich E, Moura F, Mosenzon O, Cahn A, Bhatt D, Leiter L, McGuire D, Wilding J, Gause-Nilsson I, Sabatine M, Morrow D, Wiviott S. RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58. Journal Of The American College Of Cardiology 2023, 81: 1816. DOI: 10.1016/s0735-1097(23)02260-x.Peer-Reviewed Original Research
2022
Abstract 14830: Comparative Cost-Effectiveness of Cardioprotective Glucose-Lowering Therapies for Type 2 Diabetes in a Middle-Income Country: A Bayesian Network Model
Carvalho L, Nogueira A, Antunes J, Moura F, Luchiari B, Bonilha I, Nadruz W, Gaziano M, Gaziano T, Sposito A. Abstract 14830: Comparative Cost-Effectiveness of Cardioprotective Glucose-Lowering Therapies for Type 2 Diabetes in a Middle-Income Country: A Bayesian Network Model. Circulation 2022, 146: a14830-a14830. DOI: 10.1161/circ.146.suppl_1.14830.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioGLP-1RAMiddle-income countriesType 2 diabetesCardiovascular eventsRisk of non-fatal cardiovascular eventsFollow-up >Pre-specified endpointsCohort of T2D patientsNon-fatal cardiovascular eventsGlucose-lowering therapySecondary prevention cohortAdverse cardiovascular eventsAnti-diabetic therapyRandomized clinical trialsCost-effectiveness ratioBrazilian public health systemDouble-blindGLP1-RAPublic health systemPrevention cohortProspective cohortT2D subjectsHeart failureT2D patients